Research & Education

Mesothelioma: Causes, Prevention, Screening and Early Detection

November 15, 2016 at 9:00PM EST - Recording Available

Name of Reviewer(s): 


Laurie Gaspar, MD, PhD- Advisory Board/Honoraria: Astrazeneca.

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 


Mesothelioma: Causes, Prevention, Screening and Early Detection

Date of Activity:




COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’ and/or faculty’s identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Harvey I. Pass, MD:

Grant/Research Support from:

NCI/NIH, NHLBI, CDC, DOD, Belluck and Fox, NYU Cancer Center, Patient Philanthropy, Genentech.


Honoraria from:

Astra Zeneca, IASLC, AATS


Speaker: Michele Carbone, MD-Nothing to Disclose  

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list: Unrestricted educational grant support by Bayer.



About the Program:

A recent IASLC webinar (July 27, 2016 - available on demand at addressed the role of surgery for malignant mesothelioma and updated the status of systemic therapy of this disease.  Despite advances in treatment, this disease remains a formidable challenge.  Clinical research efforts focusing on prevention and intervention at earlier stages of the disease process may improve the management of mesothelioma.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to the faculty via internet chat.

This sixty-minute webinar will feature 2 presentations:

Mesothelioma Causes and Prevention - Michele Carbone, MD

In this program, Dr. Michele Carbone will examine the causes of mesothelioma and potential prevention strategies.

The Role of Biomarker Screening to Identify Asbestos Exposed Individuals and Among Them Those who Have Developed Mesothelioma - Harvey I. Pass, MD

Dr. Harvey Pass will discuss how blood based biomarkers can be used for early detection of mesothelioma and explain the role of biomarkers to determine mesothelioma prognostication.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.


  • Define what is asbestos and how it causes cancer
  • Describe the role of genetics in mesothelioma
  • Assess the demographic differences among asbestos induced mesothelioma versus genetic or environmentally induced mesotheliomas
  • Discuss potential mesothelioma prevention strategies


  • Provide state-of-the art definitions of asbestos and mesothelioma
  • Explain the role of biomarker screening to identify asbestos exposed individuals and among them, those who have developed mesothelioma,
  • Describe the role of genetics in mesothelioma
  • Identify potential mesothelioma prevention strategies

What BARRIERS Learner will encounter:

  • Mesothelioma remains an intractable disease, survival outcomes for both early and advanced stages of disease  range from 12-25 months, thus there is significant nihilism towards this disease among community-based clinicians
  • Initiatives focusing on epidemiology, prevention, screening and early detection and systemic treatment are not yet supported by a level of clinical evidence that would change standard management of patients outside of investigational settings

How does the activity ADDRESS THE BARRIERS:

This activity reports on the scientific and clinical research focused on screening and early detection of mesothelioma. With knowledge and awareness of these efforts and a contemporary view of clinical data, the ultimate clinical adoption of such strategies will be accelerated to the benefit of patients and towards more favorable prognosis.

This activity will:

  • Assess the progress of mesothelioma clinical research in the areas of causation, prevention, screening, and early detection
  • Provides an understanding of the state –of-the- art of the role of biomarker screening to identify asbestos exposed persons and those who develop mesothelioma
  • Introduces novel concepts of potential mesothelioma prevention strategies



 Financial Commercial and Conflicts of Interest Disclosure Form

IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)



Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public.

Financial/Commercial Relationships DISCLOSURES

A conflict of interest (COI) is created and exists when individuals in a position to control the content of CME (or their spouses/partners) have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership and other activities for which remuneration is received or expected. 

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME Department assures that the planners/reviewers/authors/faculty/peer reviewers et al. conflicts of interest were identified, reviewed and resolved fromall individuals involved in the development or able to influence and control the content of this CME activity. The IASLC CME Department assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from all IASLC CME activity presentations.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee and an independent reviewer. COI will be evaluated by the IASLC Board of Directors for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. The IASLC CME Department is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making the presentation, but rather to identify and resolve any conflicts of interest that may control the content of the activity. It is also intended that any potential conflict be identified openly so that the listeners have a full disclosure of the facts and may form their own judgments about the presentation. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

All other faculty/contributors have reported no commercial affiliation associated with this conference or intent to reference off-label/unapproved uses of products or devices in their presentations.


IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.


Attendees can now view IASLC Live webinars via their mobile device.  

Downloading of the Cisco WebEx Meetings app is required.

Once the app is installed on your device you will need to enter the event number for each session.

 Registration is required for all IASLC webinars. 

Registration is on a first-come, first-served basis. Participation is limited.

How to use the Time Zone Converter